EPIX

ESSA Pharma Inc
2.99
0.05 (1.7%)
Upgrade to Real-Time
Afterhours (Closed)
2.99
Volume 141,037
Bid Price 2.91
Ask Price 3.00
News -
Day High 3.00

Low
1.40

52 Week Range

High
10.985

Day Low 2.86
Company Name Stock Ticker Symbol Market Type
ESSA Pharma Inc EPIX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.05 1.7% 2.99 20:00:00
Open Price Low Price High Price Close Price Prev Close
2.91 2.86 3.00 2.95 2.94
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,039 141,037 $ 2.92 $ 411,367 - 1.40 - 10.985
Last Trade Time Type Quantity Stock Price Currency
18:27:59 formt 1,000 $ 2.99 USD

Period:

Draw Mode:

ESSA Pharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 86.74M 29.01M 26.54M $ - $ - -0.81 -3.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 2.66M 2.50%

more financials information »

ESSA Pharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EPIX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.673.002.652.84218,7750.3211.99%
1 Month2.623.002.502.76368,2670.3714.12%
3 Months3.304.152.293.03319,502-0.31-9.39%
6 Months2.975.161.404.331,748,2340.020.67%
1 Year9.0310.9851.404.391,056,418-6.04-66.89%
3 Years5.5536.001.407.87501,809-2.56-46.13%
5 Years0.212936.000.107.65316,0832.781,304.42%

ESSA Pharma Description

ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.